Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 46

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 46
---
 eligible subjects to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly. Further, the treating physicians in our clinical trials may also use their medical discretion in advising patients enrolled in our clinical trials to withdraw from our studies to try alternative therapies.

Patient enrollment in our clinical trials for JOTROL™ and other product candidates may face challenges due to competition from ongoing trials by competitors targeting the same indications, potentially diverting eligible patients. Enrollment could also be impacted by factors such as the size and characteristics of the patient population, the severity of the disease being studied, and the availability and effectiveness of existing approved drugs. Perceptions of the risks and benefits of our novel product candidates compared to other therapies, including newly approved drugs or competing candidates, may influence clinicians and patients. Additional factors include strict patient eligibility criteria, physician referral patterns, the ability to monitor patients during and after treatment, and the influence of key opinion leaders and patient advocacy groups. The proximity and availability of clinical trial sites, along with the risk of patient dropouts or mortality due to advanced disease, could further hinder timely trial completion

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.

| 25 |

We have limited resources and are currently focusing the majority of our efforts on developing JOTROL™ for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.

We are currently focusing the majority of our resources and efforts on developing JOTROL. As a result, because we have limited resources, we may forgo or delay the pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development activities for JOTROL™ may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for JOTROL™, we may relinquish valuable rights to our product candidates